Results The patient was given Semax from August 2022 until August 2023
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
doi: 10.1007/S00204-025-03997-2 354 Averill-BatesDA
Plant Molecular Biology 77, 235249
For the average adult seeking to maintain healthy levels or boost energy, a single injection once a month is often the standard protocol
We offer innovative treatment methods like pellet-based hormone therapy to ensure your hormone treatment reaches the body in a process that feels natural
.png)
